Idiopathic short stature drug market is anticipated to grow at a significant CAGR during the forecast period. Idiopathic short stature is defined as a condition in which the height of the individual is more than 2 standard deviations (SD) below the corresponding mean height for a given sex, age, and population, in whom no identifiable disorder persists. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay. The market growth is attributed to the growing awareness amongst people about various hormone related disorders and thus, the rising number of growth hormone options available. Further, the growing prevalence of several genetic disorders such as Turner syndrome, Prader-Willi syndrome, and Noonan syndrome are also likely to provide a boost to the demand for idiopathic short stature drugs. Generally, there is no specific disorder of growth hormone (GH)/ insulin-like growth factor (IGF) and any other endocrine disorder, however in rare cases, idiopathic short stature can be associated with their cause.
Adding to this, the availability of insurance benefit in the developed economies such as the US further boosts the penetration of the biosimilar or biologics drugs used in the treatment of idiopathic short stature. While various treatment options are in the market majority of these are not approved for growth acceleration and hence, they are considered under off label use. Recombinant growth hormone therapy, Insulin like Growth Factor -1 (IGF-1) therapy, Aromatase inhibitors and low-dose androgen therapy (with injectable testosterone and low dose androgen) are some of the treatment options that have gain prominence in the past few years.
To Request a Sample of our Report on Idiopathic Short Stature Drug Market: https://www.omrglobal.com/request-sample/idiopathic-short-stature-drug-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Product Type
- By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Pfizer Inc., and Eli Lilly and Co., among others.
A full Report of Idiopathic Short Stature Drug Market is Available @ https://www.omrglobal.com/industry-reports/idiopathic-short-stature-drug-market
Idiopathic Short Stature Drug Market Report by Segment
By Product
- BBT-031
- MMP-0201
- Somatropin
- Others
By Application
- Hospital
- Clinic
- Research Center
Idiopathic Short Stature Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
